How medicare could get better prices on prescription drugs

Health Affairs

Volumn 28, Issue 5, 2009, Pages

  Outterson, Kevin ^a   Kesselheim, Aaron S ^b  

^a BOSTON UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG; UNCLASSIFIED DRUG;

ARTICLE; DRUG COST; DRUG FORMULARY; GOVERNMENT; HEALTH CARE PLANNING; HEALTH CARE POLICY; MEDICARE; PRESCRIPTION;

COST SAVINGS; DRUG COSTS; HEALTH CARE REFORM; HUMANS; MEDICARE PART D; PRESCRIPTION DRUGS; RATE SETTING AND REVIEW; UNITED STATES;

EID: 70349197850     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.5.w832     Document Type: Article

References (44)

1. Families USA. No bargain: Medicare drug plans deliver high prices [Internet]. Washington (DC): Families USA; 2007 Jan [cited 2009 Jun 11]. Available from: http://www.familiesusa.org/assets/pdfs/no-bargainmedicare-drug. pdf
2. Congressional Budget Office. Budget options volumeI: health care [Internet]. Washington (DC): CBO; 2008 Dec [cited 2009 Jun 11]. Available from: http://www.cbo.gov/ftpdocs/99xx/doc9925/12-18-HealthOptions.pdf
3. CBO. Issues regarding drug price negotiation in Medicare, letter to the Honorable Ron Wyden [Internet]. Washington (DC): CBO: 2007 Apr 10 [cited 2009 Jun 11]. Available from: http://www.cbo.gov/ftpdocs/79xx/doc7992/ DrugPriceNegotiation.pdf
4. U.S. Government Accountability Office. Prescription drugs: expanding access to federal prices could cause other price changes [Internet]. Washington (DC): GAO; 2000 Aug [cited 2009 Jun 11]. Available from: http://www.gao.gov/ archive/2000/he00118.pdf
5. Gellad WF, Schneeweiss S, Brawarsky P, Lipsitz S, Haas JS. What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings. J Gen Intern Med. 2008;23(9):1435-1440
6. Medicare Prescription Drug Savings and Choice Act, S 330, 111th Cong., 1st Sess. (2009).
7. Lopert R, Moon M. Toward a rational, value-based drug benefit for Medicare. Health Aff (Millwood). 2007;26(6):1666-1673
8. Dicken JE. An overview of approaches to negotiate drug prices used by other countries and US private payers and federal programs. Washington (DC): GAO; 2007 Jan 11. Report no. GAO-070358T.
9. Frank RG, Newhouse JP. Should drug prices be negotiated under Part D of Medicare? And if so, how? Health Aff (Millwood). 2008;27(1):33-43.
10. House Committee on Oversight and Government Reform, Majority Staff. Medicare Part D: drug pricing and manufacturer windfalls [Internet]. Washington (DC): U.S. House of Representatives; 2008 Jul [cited 2009 Jun 11]. Available from: http://oversight.house.gov/documents/20080724101850.pdf
11. West JC, Wilk JE, Muszynski IL, Rae DS, Rubio-Stipec M, Alter CL, et al. Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first four months of the Medicare prescription drug benefit. Am J Psychiatry. 2007;164(5):789-796 (Pubitemid 46808534)
12. Shrank WH, Patrick AR, Pedan A, Polinski JM, Varasteh L, Levin R, et al. The effect of transitioning to Medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. J Am Geriatr Soc. 2008;56(12):2304-2310
13. Texas v. Leavitt, 547 US 1204 (2006).
14. Outterson K. Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale J Health Policy Law Ethics. 2005;5(1):193-291.
15. Schoen C, Guterman S, Shih A, Lau J, Kasimow S, Gauthier A, et al. Bending the curve: options for achieving savings and improving value in U.S. health spending [Internet]. New York (NY): Commonwealth Fund; 2007 Dec 18 [cited 2009 Jun 11]. Available from: http://www.commonwealthfund.org/Content/ Publications/Fund-Reports/2007/Dec/Bending-the-Curve-Options-for-Achieving- Savings-and-Improving-Value-in-U-S--Health-Spending.aspx
16. U.S. House Committee on Oversight and Government Reform, Majority Staff. Private Medicare drug plans: high expenses and low rebates increase the costs of Medicare drug coverage [Internet]. Washington (DC): U.S. House of Representatives; 2007 Oct [cited 2009 Jun 11]. Available from: http://oversight.house.gov/documents/20071015093754.pdf
17. U.S. Pharmacopeia. Revising the Medicare model guidelines. Rockville (MD): U.S. Pharmacopeia; 2004 Dec 31 [cited 2009 Jul 15]. Available from: http://www.usp.org/hqi/mmg/revisions.html
18. Centers for Medicare and Medicaid Services. Medicare Modernization Act: 2007 final guidelines - formularies [Internet]. Baltimore (MD): CMS; 2007 [cited 2009 Jun 11]. Available from: http://www.cms.hhs.gov/PrescriptionDrugCovContra/ DOWNLOADS/CY07formularyguidance.pdf
19. Medicare Payment Advisory Commission. A data book: healthcare spending and the Medicare program [Internet]. Washington (DC): MedPAC; 2008 Jun [cited 2009 Jun 11]. Available from: http://www.medpac.gov/documents/Jun08DataBook- Entire-report.pdf
20. Medicare Improvements for Patients and Providers Act, PL 110-275 (2008 Jul 15).
21. Kipp RA, Ko C. Potential cost impacts resulting from CMS guidance on special protections for six protected drug classifications and Section 176 of the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA) (P.L. 110-275) [Internet]. Academy of Managed Care Pharmacy; 2008 Oct 16 [cited 2009 Jun 11]. Available from: http://www.amcp.org/amcp.ark?p=AA8CD7EC
22. CBO. Prescription drug pricing in the private sector [Internet]. Washington (DC): CBO; 2007 Jan [cited 2009 Jun 11]. Available from: http://www.cbo.gov/ftpdocs/77xx/doc7715/01-03-PrescriptionDrug.pdf
23. Block AL. Letter to Part D sponsors: formulary changes during the plan year [Internet]. Baltimore (MD): CMS; 2006 Apr 27 [cited 2009 Jun 11]. Available from: http://www.cms.hhs.gov/PrescriptionDrugCovContra/downloads/ MemoFormularyChangeGuidance-04.27.06.pdf
24. Gruber J. Choosing a Medicare Part D plan: are Medicare beneficiaries choosing low-cost plans? [Internet]. Menlo Park (CA): Kaiser Family Foundation; 2009 Mar [cited 2009 Jun 11]. Available from: http://www.kff.org/medicare/ upload/7864.pdf
25. Kesselheim AS, Fischer MA, Avorn J. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on Medicaid spending. Health Aff (Millwood). 2006;25(6):1637-1647 (Pubitemid 44871732)
26. Aitken M, Berndt ER, Cutler DM. Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff (Millwood). 2009;28(1):w151-60.
27. Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients' perceptions of generic medications. Health Aff (Millwood). 2009;28(2):546-556
28. CMS. Part D generic drug utilization rates (2006-2008) [Internet]. Baltimore (MD): CMS; 2009 May 28 [cited 2009 Jun 11]. Available from: http://www.cms.hhs.gov/PrescriptionDrugCovGenIn/06-PerformanceData.asp
29. Nightingale SL. Therapeutic equivalence of generic drugs: letter to health practitioners [Internet]. Rockville (MD): Food and Drug Administration; 1998 Jan 28 [cited 2009 Jun 11]. Available from: http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/ AbbreviatedNewDrugApplicationANDAGenerics/ucm073182.htm
30. This practice is sometimes called reference-based pricing, but it is distinct from international reference pricing.
31. Blum J. Issuance of the 2010Call Letter [Internet]. Baltimore (MD):CMS; 2009 Mar 30 [cited 2009 Jun 11]. Available from: http://www.cms.hhs.gov/ PrescriptionDrugCovContra/Downloads/2010CallLetter.pdf
32. Pharmaceutical Market Access and Drug Safety Act, S 525, 111th Cong., 1st Sess. (2009).
33. Anderson GF, Shea DG, Hussey PS, Keyhani S, Zephyrin L. Doughnut holes and price controls. Health Aff (Millwood). 2004;23:w4-396-404.
34. Kesselheim AS, Choudhry NK. The international pharmaceutical market as a source of low-cost prescription drugs for U.S. patients. Ann Intern Med. 2008;148(8):614-619
35. Danzon PM. Closing the doughnut hole: no easy answers. Health Aff (Millwood). 2004;23:w4-405-408
36. MedPAC. Report to the Congress: reforming the delivery system [Internet]. Washington (DC): MedPAC; 2008 Jun [cited 2009 Jun 11]. Available from: http://www.medpac.gov/documents/Jun08-EntireReport.pdf
37. Jayadev A, Stiglitz J. Two ideas to increase innovation and reduce pharmaceutical costs and prices. Health Aff (Millwood). 2008;28(1):w165-8.
38. MedPAC. Report to the Congress: improving incentives in the Medicare program [Internet]. Washington (DC): MedPAC; 2009 Jun [cited 2009 Jun 15]. Available from: http://www.medpac.gov/documents/Jun09-EntireReport.pdf
39. Steinbrook R. Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med. 2008;359(19):1977- 1981
40. Moon M, Smith B, Gustafson S. Creating a center for evidence-based medicine [Internet]. Washington (DC): MedPAC; 2008 Feb [cited 2009 Jun 11]. Available from: http://www.medpac.gov/documents/Feb08-Center-EvidenceBased- CONTRACTOR-NR.pdf
41. Duckett SJ. Drug policy down under: Australia's Pharmaceutical Benefits Scheme. Health Care Financ Rev. 2004;25(3):55-67.
42. Neumann PJ. Emerging lessons from the Drug Effectiveness Review Project. Health Aff (Millwood). 2006;25:w262-71.
43. Clancy CM, Cronin K. Evidence-based decision making: global evidence, local decisions. Health Aff (Millwood). 2005;24(1):151-162 (Pubitemid 40173937)
44. Institute of Medicine. Initial national priorities for comparative effectiveness research. Chap. 2. Washington (DC): National Academies Press; 2009.